SAN FRANCISCO -- The pediatric Crohn's disease exclusion diet was associated with clinical remission for children with good ...

IBD Aware, a wearable medical device in development for patients with inflammatory bowel disease, aims to improve disease ...

Phil Johnson started about four months ago as chief commercial officer at Evidation. He sat down on the sidelines of JP ...

Bushra Sumra’s career highlights the profound impact that expertise in clinical research and regulatory compliance can have ...

The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BAT2506 as a biosimilar to reference p ...

Eli Lilly (NYSE:LLY) reported positive results from an open-label study of its drug Omvoh in the treatment of moderately to severely active Crohn's disease. The study, called VIVID-2, showed that the ...

Men with inflammatory bowel disease face a higher risk for ischemic heart diseases, according to study findings.

The report suggests that USAID could have seen its 10,000-strong workforce reduced to just 300, with the new figure emerging ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

PORTLAND, OR, UNITED STATES, February 7, 2025 /EINPresswire / -- The global ulcerative colitis (UC) market is ex ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion ...